The identification of driver mutations and drugs that inhibit their activity has been a major therapeutic advance for patients with advanced lung adenocarcinoma
The sentinel lymph node biopsy(SLNB)was initially pioneered for staging melanoma in 1994 and it has been subsequently validated by several trials,and has become